hotspot -WSS

hotspot

author：knowledge 2025-09-28 05:12:09 Page View：22654

Zepbound, a injectable drug on a gradient background of dark purple and green — biotech coverage from STAT — Illustration: STAT; Source: Eli Lilly/AP

A California biotech developing a combination therapy with the obesity drug Zepbound has raised a $170 million Series D round.

The company, BioAge, raised money from more than a dozen investors. Sofinnova Investments led the round, which also included Eli Lilly and Amgen’s venture arms and previous investor Andreessen Horowitz.

BioAge’s primary focus is in developing medications that boost a person’s healthspan, or the number of healthy years a person lives. The company has drugs in development for neuroinflammation and brain aging. But the majority of the Series D proceeds will be used to develop the company’s lead drug candidate azelaprag, which is being tested in combination with Zepbound. That drug program is what grabbed Sofinnova’s attention, according to managing partner Jim Healy, who recently became chairman of BioAge’s board.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Patients, doctors press FTC to beef up hospital merger scrutiny
Next article： Affirmative action in medical school literally saved lives

focus

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

The SUPPORT Act is critical to fighting the opioid crisis

AdobeFewpublichealthchallengeshavebeenmoredauntingandpersistentthantheopioidcrisis,whichstartedbecau

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Fed up with FDA, ALS advocates consider a take

Ademonstrationmarkingthe10thanniversaryoftheformationACTUP,inNewYork.MarkLennihan/APWASHINGTON—NextW

hotspot

explore

focus

Fed up with FDA, ALS advocates consider a take